

Availability of data and materials

Not applicable.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Available on request.

Competing interests

The authors declare no competing interests.

Received: 1 September 2022 Accepted: 25 January 2023

Published online: 31 January 2023

References

1. Fitzmaurice C, Allen C, Barber RM, Barregard L, et al. A systematic analysis for the global burden of disease study. *JAMA Oncol.* 2017;3(4):524–48. <https://doi.org/10.1001/jamaoncol.2016.5688>. Erratum In: *JAMA Oncol.* 2017Mar1;3(3):418.
2. Surveillance, Epidemiology, and End Results (SEER) 18 registries, National Cancer Institute, 2021. <https://seer.cancer.gov>
3. Saigal CS, Gore JL, Krupski TL, Hanley J, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. *Cancer.* 2007;110:1493–500. <https://doi.org/10.1002/cncr.22933>
4. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. *J Clin Oncol.* 2016;34(18):2098–106.
5. Cone EB, Reese S, Marchese M, Nabi J, et al. Cardiovascular toxicities associated with Abiraterone compared to enzalutamide—a pharmacovigilance study. *EClinicalMedicine.* 2021;36:100887.
6. Lee HY, Chen HL, Teoh JY, Chen TC, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. *Prostate Cancer Prostatic Dis.* 2021;24(1):244–52. <https://doi.org/10.1038/s41391-020-00275-3>
7. Lacovelli R, Ciccarese C, Bria E, Romano M, et al. The cardiovascular toxicity of Abiraterone and Enzalutamide in prostate cancer. *Clin Genitourin Cancer.* 2018;16(3):e645–53.
8. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med.* 2014;371:424–33. <https://doi.org/10.1056/NEJMoa1405095>.
9. Moreira RB, Debiasi M, Francini E, Nuzzo PV, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. *Oncotarget.* 2017;8(48):84572–8. <https://doi.org/10.18632/oncotarget.20028>.
10. Shrestha B, Gouli S, Shrestha A. Abstract 16180: Cardiovascular adverse events associated with androgen receptor-targeted therapy used in the treatment of prostate cancer. https://doi.org/10.1161/circ.142.suppl_3.16180 *Circulation.* 2020;142:A16180

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions